Alipour Azita, Gabrielson Stephen, Patel Puja Baldev
College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA 92831, USA.
Health Sciences Library System, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Pharmacy (Basel). 2020 Jun 16;8(2):103. doi: 10.3390/pharmacy8020103.
Poor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. The high rates of antipsychotic non-adherence continue to persist despite several interventions and medication advances. This review evaluates the possible role of the ingestible sensor technology for medication adherence in different conditions, with a focus on use in the SMI schizophrenia.
Literature searches were conducted in July 2019 in the PubMed database.
In small studies of ingestible sensor use, the average adherence ranged from 73.9% to 88.6% for SMI and ≥ 80% for cardiac and transplant (99.4%) patients. In SMI studies, patients were clinically stable, and the majority had a clinical global impression severity of "mild disease". Patients generally experienced relatively minor dermatological adverse effects related to wearable sensor use.
A medication with an ingestible sensor may help provide real-time objective medication-taking adherence information for clinicians. However, further studies are needed to understand the impact of use on adherence and improvement on treatment outcomes with the ingestible sensor technology.
药物依从性差是一个重大的公共卫生问题。患有严重精神疾病（SMI）的患者通常存在不遵守药物治疗方案的情况，这可能导致病情复发和住院。尽管采取了多种干预措施并取得了药物进展，但抗精神病药物的高不依从率仍然持续存在。本综述评估了可摄入传感器技术在不同情况下对药物依从性的可能作用，重点关注其在SMI精神分裂症中的应用。
2019年7月在PubMed数据库中进行了文献检索。
在关于可摄入传感器使用的小型研究中，SMI患者的平均依从率为73.9%至88.6%，心脏和移植患者（99.4%）的平均依从率≥80%。在SMI研究中，患者临床稳定，大多数患者的临床总体印象严重程度为“轻度疾病”。患者通常经历与可穿戴传感器使用相关的相对较小的皮肤不良反应。
带有可摄入传感器的药物可能有助于为临床医生提供实时客观的服药依从性信息。然而，需要进一步研究以了解使用该技术对依从性的影响以及对治疗结果的改善情况。
